Biolase (NASDAQ:BIOL) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.17) by 111.76 percent. The company reported quarterly sales of $10.131 million which beat the analyst consensus estimate of $9.996 million by 1.35 percent. This is a 3.21 percent decrease over sales of $10.467 million the same period last year.
Biolase Q1 2024 Adj EPS $(0.36) Misses $(0.17) Estimate, Sales $10.131M Beat $9.996M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.